CELSION CORP (CLSN) Stock Price & Overview

NASDAQ:CLSN • US15117N6022

1.96 USD
0 (0%)
At close: Sep 20, 2022
1.96 USD
0 (0%)
After Hours: 9/20/2022, 8:01:31 PM

The current stock price of CLSN is 1.96 USD. Today CLSN is down by 0%. In the past month the price decreased by -15.52%. In the past year, price decreased by -87.06%.

CLSN Key Statistics

52-Week Range1.8 - 15.75
Current CLSN stock price positioned within its 52-week range.
1-Month Range1.91 - 2.56
Current CLSN stock price positioned within its 1-month range.
Market Cap
13.914M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-7.21
Dividend Yield
N/A

CLSN Stock Performance

Today
0%
1 Week
-6.67%
1 Month
-15.52%
3 Months
+3.16%
Longer-term
6 Months -64.30%
1 Year -87.06%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

CLSN Stock Chart

CELSION CORP / CLSN Daily stock chart

CLSN Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to CLSN. When comparing the yearly performance of all stocks, CLSN is a bad performer in the overall market: 85.28% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
CLSN Full Technical Analysis Report

CLSN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CLSN. CLSN may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CLSN Full Fundamental Analysis Report

CLSN Earnings

Next Earnings DateNov 14, 2022
Last Earnings DateAug 15, 2022
PeriodQ2 / 2022
EPS Reported-$0.87
Revenue Reported
EPS Surprise 24.01%
Revenue Surprise 50.83%
CLSN Earnings History

CLSN Forecast & Estimates

8 analysts have analysed CLSN and the average price target is 27.54 USD. This implies a price increase of 1305.1% is expected in the next year compared to the current price of 1.96.


Analysts
Analysts82.5
Price Target27.54 (1305.1%)
EPS Next Y21.32%
Revenue Next Year0%
CLSN Forecast & Estimates

CLSN Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

CLSN Financial Highlights

Over the last trailing twelve months CLSN reported a non-GAAP Earnings per Share(EPS) of -7.21. The EPS decreased by -35.02% compared to the year before.


Income Statements
Revenue(TTM)500.00K
Net Income(TTM)-26.15M
Industry RankSector Rank
PM (TTM) -5229.82%
ROA -40.03%
ROE N/A
Debt/Equity 0.13
Chartmill High Growth Momentum
EPS Q2Q%3.33%
Sales Q2Q%0%
EPS 1Y (TTM)-35.02%
Revenue 1Y (TTM)-2.91%
CLSN financials

CLSN Ownership

Ownership
Inst Owners0.31%
Shares7.10M
Float7.06M
Ins Owners37.95%
Short Float %N/A
Short RatioN/A
CLSN Ownership

CLSN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC14.8398.492B
AMGN AMGEN INC16.04198.265B
GILD GILEAD SCIENCES INC16.4180.267B
VRTX VERTEX PHARMACEUTICALS INC24.21121.459B
REGN REGENERON PHARMACEUTICALS15.9578.932B
ALNY ALNYLAM PHARMACEUTICALS INC42.0142.071B
INSM INSMED INC N/A30.073B
BIIB BIOGEN INC11.2927.136B
NTRA NATERA INC N/A26.973B
UTHR UNITED THERAPEUTICS CORP17.9523.353B
MRNA MODERNA INC N/A21.086B
EXAS EXACT SCIENCES CORP340.7419.713B
RVMD REVOLUTION MEDICINES INC N/A18.84B

About CLSN

Company Profile

CLSN logo image Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.

Company Info

IPO: 1993-10-27

CELSION CORP

997 Lenox Dr Ste 100

Lawrence Township NEW JERSEY 08648 US

CEO: Michael H. Tardugno

Employees: 29

CLSN Company Website

Phone: 16098969100.0

CELSION CORP / CLSN FAQ

What does CLSN do?

Celsion Corp .is a clinical stage oncology drug company. The company is headquartered in Lawrence Township, New Jersey and currently employs 29 full-time employees. The firm is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The firm's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. The company has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.


Can you provide the latest stock price for CELSION CORP?

The current stock price of CLSN is 1.96 USD.


Does CLSN stock pay dividends?

CLSN does not pay a dividend.


How is the ChartMill rating for CELSION CORP?

CLSN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


When does CELSION CORP (CLSN) report earnings?

CELSION CORP (CLSN) will report earnings on 2022-11-14.


Can you provide the ownership details for CLSN stock?

You can find the ownership structure of CELSION CORP (CLSN) on the Ownership tab.